RYE, N.Y., Aug. 26, 2013 /PRNewswire/ -- Curemark, a drug research and development company focused on neurological disorders, announced today that it has entered into a collaborative research agreement with the VTT/MSI Molecular Sciences Institute (MSI) in Berkeley, CA.
Founded in 1996 by Nobel-prize winner Sydney Brenner, MSI is an independent, not-for-profit research institute. In 2011, MSI created a partnership in bioengineering with VTT (Technical Research Centre of Finland) that is now known as the VTT/MSI Molecular Sciences Institute. VTT/MSI's Center for Bioengineering strives to contribute to the understanding of biology to improve human health and positively impact society.
Curemark's Chief Scientific Officer Dr. Matthew Heil said, "Tapping into MSI's expertise will deepen our knowledge of the full nature of our proprietary enzyme's biological properties. We expect this research will lead to multiple additional indications and formulation possibilities, which will benefit people with unmet medical needs."
Dr. Orna Resnekov, VTT/MSI Director, echoed Dr. Heil's sentiments. "We are excited to work with Curemark, the leader in novel therapies for autism, to advance the company's exciting research and development program," she said.
Curemark is currently developing a treatment for autism, CM-AT, which the U.S. Food and Drug Administration (FDA) has granted its Fast Track designation. The FDA Fast Track program facilitates the development and expedites the review of new drugs that are intended to treat serious or life-threatening conditions, and that demonstrate the potential to meet unmet medical needs.
Curemark previously announced successful preliminary discussions with the FDA regarding the anticipated
|SOURCE Curemark LLC|
Copyright©2012 PR Newswire.
All rights reserved